Design, Synthesis and Biological Evaluation of Histone Deacetylase Inhibitors Based on Pyrrolo[2,3‐ d ]pyrimidine and Pyrrolo[2,3‐ b ]pyridine Scaffolds
ChemMedChem · 2023
DOI: 10.1002/cmdc.202200683 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2023. Verfasst von Nian-Dong Mao und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Hangzhou Normal University, Hangzhou, China. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Department of Zhejiang Province.
Abstract (Originalsprache)
Histone deacetylases (HDACs) are validated targets for the development of anticancer drugs in epigenetics. We have designed and synthesized a series of novel HDAC inhibitors based on pyrrolo[2,3‐ d ]pyrimidine and pyrrolo[2,3‐ b ]pyridine scaffolds. Compound B3 {( E )‐3‐(4‐(((1‐(7 H ‐pyrrolo[2,3‐ d ]pyrimidin‐4‐yl)piperidin‐4‐yl)amino)methyl)phenyl)‐ N ‐hydroxyacrylamide} exhibits potent inhibitory activity against HDACs 1, 2, 3, 6, and 8 with IC 50 values of 5.2, 6.0, 8.8, 4.4, and 173.0 nM, respectively. It exhibited potent antiproliferative effects against three tumour cell lines (IC 50 values of 0.13, 0.37, and 1.11 μM, against MV‐4‐11, K562, and WSU‐DLCL‐2 cells, respectively) with two‐ to sixfold improvement relative to suberoylanilide hydroxamic acid (SAHA). Mechanistic studies on WSU‐DLCL‐2 cells revealed that B3 exhibits anticancer effects through the induction of G 0 /G 1 ‐phase arrest and promotion of apoptosis. The results of this study warrant further investigation of this compound series for the treatment of hematological malignancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Hangzhou Normal University, Hangzhou, China.
- Key Laboratory of Elemene Class Anti-Cancer Chinese Medicine of Zhejiang Province, Hangzhou, China.
- Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Hangzhou, China.
- t/>Collaborative Innovation Center of Chinese Medicines from, Zhejiang Province, Hangzhou, China.
- Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- School of Basic Medical Science, Hangzhou Normal University, Hangzhou, China.
ORCID-Profile: Xingrui He, Xiang-Yang Ye
Förderung
- National Natural Science Foundation of China
- Science and Technology Department of Zhejiang Province
Zitieren
APA
Mao, N. D., Gao, Y., Dang, X. W., Duan, J. L., Hui, Z., Che, H., Xu, Y., Zhang, H., He, X., Garrido, C., & Ye, X. Y. (2023). Design, Synthesis and Biological Evaluation of Histone Deacetylase Inhibitors Based on Pyrrolo[2,3‐ d ]pyrimidine and Pyrrolo[2,3‐ b ]pyridine Scaffolds. ChemMedChem. https://doi.org/10.1002/cmdc.202200683
Vancouver
Mao ND, Gao Y, Dang XW, Duan JL, Hui Z, Che H, et al. Design, Synthesis and Biological Evaluation of Histone Deacetylase Inhibitors Based on Pyrrolo[2,3‐ d ]pyrimidine and Pyrrolo[2,3‐ b ]pyridine Scaffolds. ChemMedChem. 2023. doi:10.1002/cmdc.202200683
BibTeX
@article{Mao2023,
author = {Mao, Nian-Dong and Gao, Yuan and Dang, Xia-Wen and Duan, Ji-Long and Hui, Zi and Che, Hao and Xu, Yueying and Zhang, Hang and He, Xingrui and Garrido, Carmen and Ye, Xiang-Yang},
title = {Design, Synthesis and Biological Evaluation of Histone Deacetylase Inhibitors Based on Pyrrolo[2,3‐ d ]pyrimidine and Pyrrolo[2,3‐ b ]pyridine Scaffolds},
journal = {ChemMedChem},
year = {2023},
doi = {10.1002/cmdc.202200683}
}
EUVIMED